Lundbeck's acquisition of Ovation Pharmaceuticals cleared by US Federal Trade Commission

H. Lundbeck A/S' acquisition of Ovation Pharmaceuticals, Inc,
announced on 9 February 2009, has successfully closed following
expiration of the 30-day review period required by the U.S. Federal
Trade Commission under the Hart-Scott-Rodino Act.
On 9 February 2009 Lundbeck announced that it had reached agreement
to acquire Ovation in an all cash transaction valuing Ovation at up
to USD 900 million or approximately DKK 5.2 billion. The acquisition
of Ovation delivers on Lundbeck's strategic goal to build a
commercial infrastructure in the US. Ovation is a private, US-based,
profitable and fast growing company, with a broad portfolio of
marketed products and an attractive pipeline of new, innovative CNS
products. The pipeline is expected to significantly drive growth in
the coming years through multiple new product launches.

Following the transaction Lundbeck will have a diverse portfolio of
marketed products and a broader pipeline of CNS compounds.

Lundbeck's Chief Executive Officer Ulf Wiinberg commented:"We are delighted that the acquisition of Ovation is finalised. The
acquisition of Ovation represents a major step in the establishment
of a US commercial platform and brings important products and a
pipeline that will broaden our presence within CNS even further. We
see significant growth opportunities from Ovation in the years to

The final FTC clearance and the subsequent integration of Ovation
will impact Lundbeck's guidance for 2009 as communicated on 4 March
2009. Lundbeck expects to provide financial guidance including
Ovation in connection with the half year report 2009 at the latest.

Following today's announcement Ovation will become a fully-integrated
subsidiary of Lundbeck and will change its name to Lundbeck Inc.

Ovation background
Based in Deerfield, IL, Ovation was founded in 2000 with a focused
strategy to acquire and develop specialty compounds for the US market
for severely ill patients with high unmet medical needs.

Today, the company has a broad portfolio of medicines - both approved
and in development. Fueled by a promising CNS specialty pipeline, the
company expects a number of near-term product launches and these new
medicines will treat a variety of serious and debilitating

Products on the market to address CNS disorders include Xenazine® for
chorea associated with Huntington's disease, Tranxene® for anxiety
disorders, Nembutal® for acute convulsive disorders, Cogentin® for
Parkinson's disease and Desoxyn® for ADHD. Outside CNS disorders the
products Ovation markets include ATryn®, just approved by the U.S.
Food and Drug Administration for the prevention of thromboembolic
events in hereditary antithrombin deficient (HAD) patients in
high-risk situations such as surgery or childbirth procedures, a
portfolio of hospital-based products, and haematology/oncology
therapies, including Panthematin® for recurrent attacks of acute
intermittent porphyria temporally related to the menstrual cycle in
susceptible women.

The product pipeline at Ovation is predominantly focused on CNS
disorders and includes Sabril® for adults with refractory complex
partial seizures and children with infantile spasms, two indications
that have recently been unanimously recommended for approval by the
Peripheral and Central Nervous System Drugs Advisory Committee
appointed by the US FDA, clobazam in clinical phase III for
Lennox-Gastaut Syndrome and an IV formulation of carbamazepine in
clinical phase III for epilepsy.

The company employs 283 employees, which includes a specialised and
experienced sales force of 68 employees and a highly experienced and
dedicated management team that will stay with the company following
the transaction.

For patients, relatives and caregivers
Today's announcement will not affect or interfere with any product
availability or support for any of the products that Ovation
currently has on the market. Likewise, there will be no changes to
the availability or support provided for Lundbeck's currently
marketed products.

Financial guidance
Lundbeck's full year guidance for 2009 at this time does not include
Ovation. Lundbeck expects to provide financial guidance including
Ovation in connection with the half year report 2009 at the latest.

Lundbeck contacts

Investors:                 Media:

Jacob Tolstrup             Mads Vindahl Kronborg
Director                   Media Relations
+45 36 43 30 79            +45 36 43 28 51

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26

Release No 369 - 19 March 2009

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international
pharmaceutical company engaged in the research and development,
production, marketing and sale of pharmaceuticals for the treatment
of psychiatric and neurological disorders. In 2008, the company's
revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD
2.2 billion). The number of employees is approx 5,500 globally. For
more information, please visit


Documents & Links